戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  self-efficacy), and health behaviors (e.g., medication adherence).
2 flicts with participants' own high rating of medication adherence.
3  subjective well-being and immunosuppressive medication adherence.
4  distributed through daily lotteries tied to medication adherence.
5 ypertensive medications and interfering with medication adherence.
6 tient relationships, patient engagement, and medication adherence.
7 stically significant improvement in glaucoma medication adherence.
8 ts were largely consistent when adjusted for medication adherence.
9 bout their health and their attitudes toward medication adherence.
10 rug treatment plan are associated with lower medication adherence.
11  subgroup analysis by anatomic location, and medication adherence.
12 e-based strategy for monitoring tuberculosis medication adherence.
13 tection appears to be highly correlated with medication adherence.
14 dge of glaucoma, and perceptions of glaucoma medication adherence.
15  that are optimized for clinic retention and medication adherence.
16 een developed to simplify dosing and improve medication adherence.
17 ess, treatment, control, or antihypertensive medication adherence.
18 social predictors that will lead to improved medication adherence.
19 ife chaos may be an important determinant of medication adherence.
20 ponents as working together to improve their medication adherence.
21 this high-risk patient population to improve medication adherence.
22  multiple sources of information to quantify medication adherence.
23 eases in sexual risk despite low to moderate medication adherence.
24 s, reduced out-of-pocket costs, and improved medication adherence.
25 ther 95% or greater or less than 95% overall medication adherence.
26 e, and finally, (5) interventions to improve medication adherence.
27  of the copayment increase on lipid-lowering medication adherence.
28 less of whether patients had good or poor BP medication adherence.
29 sion control in diabetes care independent of medication adherence.
30 nly 35% of bipolar adolescents reported full medication adherence.
31 ractures, fracture rates and disutility, and medication adherence.
32 predicted a 2.4-percentage-point decrease in medication adherence.
33 atient visits, and negative attitudes toward medication adherence.
34 , and biologic variables on antihypertensive medication adherence.
35 d model included the additional covariate of medication adherence.
36  relapse, depressive and manic symptoms, and medication adherence.
37 a, knowledge is limited about how to improve medication adherence.
38 ment of strategies to establish and maintain medication adherence.
39  coping strategies and counseling to improve medication adherence.
40 ceted intervention can help improve glaucoma medication adherence.
41 y recorded data and a lack of information on medication adherence.
42 social, and spiritual domains, and increased medication adherence.
43 -pocket costs may be associated with reduced medication adherence.
44 nt (95% CI, 0.06-0.92) in the probability of medication adherence.
45           Change in electronically monitored medication adherence.
46 g therapeutic inertia, and improving patient medication adherence.
47 and the lack of clinical outcomes, including medication adherence.
48 t strategies to reduce risk should emphasize medication adherence.
49 ential to improve acceptability and increase medication adherence.
50 iated through the effects of cannabis use on medication adherence.
51 outine care, and has reproducible effects on medication adherence.
52 nt of education, perceived stress, race, and medication adherence.
53 ecutive function, or memory predicted 21-day medication adherence.
54  with worse short-term and long-term patient medication adherence.
55 onent of the treatment, we also searched for medication adherence." 2.
56  those taking medications reported increased medication adherence; 26% to 36% had privacy concerns; 1
57 a result of the multiple factors influencing medication adherence, a patient-centered approach that t
58 f opioid dependence is limited by suboptimal medication adherence, abuse, and diversion.
59 dabigatran, there was variability in patient medication adherence across Veterans Health Administrati
60 atients and by clinicians is associated with medication adherence, adjusting for clinician clustering
61  impact of patient-provider communication on medication adherence among a sample of primary care prov
62  examine the impact of cognitive function on medication adherence among community-dwelling patients w
63 ng data (n = 1,817) from the Cohort Study of Medication Adherence among Older Adults (recruitment con
64 ially in regard to memory, predicted reduced medication adherence among patients with HF and no histo
65 here remain opportunities for improvement in medication adherence among patients with prescription dr
66      Evidence-based interventions to improve medication adherence among patients with schizophrenia a
67  afford medication is a major determinate of medication adherence among patients.
68 idence-based nursing intervention to improve medication adherence among people living with HIV/AIDS a
69 t increase adversely affected lipid-lowering medication adherence among veterans, including those at
70 ng were related to subjective well-being and medication adherence among young adult kidney transplant
71 herence to medication regimens (hereinafter "medication adherence") among older adults after MI.
72 e objectives of the study were to (a) assess medication adherence and (b) to identify emotionality an
73             Secondary outcomes included both medication adherence and a composite end point of all-ca
74 roups received behavioral therapy focused on medication adherence and a second dose of XR-naltrexone.
75  atherosclerosis by 25% by 2025 by improving medication adherence and access, but further trial data
76 sease, providers should identify barriers to medication adherence and actively engage patients in sha
77 oid regimen (supervised therapy) can improve medication adherence and asthma control.
78  multifactorial intervention to improve both medication adherence and blood pressure control and to r
79           Counseling of patients with CHB on medication adherence and confirmation of VBT and/or GR c
80 f the intervention is effective in improving medication adherence and demonstrating a lower cost, the
81 s that programs are feasible and may improve medication adherence and disease outcomes.
82 etrimental effects of release from prison on medication adherence and disease progression among HIV-p
83                    Treatments that emphasize medication adherence and early recognition of mood sympt
84 on, and pharmaceutical databases may improve medication adherence and have a positive effect on cardi
85 s have highlighted the importance of patient medication adherence and have outlined factors that affe
86 es are broadly applicable or affect longterm medication adherence and health outcomes.
87 ent themes focused on overcoming barriers to medication adherence and included cues to action, statem
88  blood pressure (BP) control because of poor medication adherence and lack of medication intensificat
89 Objective: To assess the association between medication adherence and medical homes in a national pat
90            To assess the association between medication adherence and medical homes in a national pat
91 sideration of DDIs is paramount to improving medication adherence and mitigating adverse effects duri
92 nt outcomes by reinforcing the importance of medication adherence and persistence and by recognizing
93 s provided limited and heterogeneous data on medication adherence and persistence.
94 of the program was associated with decreased medication adherence and persistence.
95                              Improvements in medication adherence and prescribing could have a substa
96 easibility was assessed as recruitment rate, medication adherence and procedural adherence.
97  intervention, the telecare group had better medication adherence and quality of life than the contro
98      Enhanced prescription coverage improved medication adherence and rates of first major vascular e
99 n a free-medicine program alone in improving medication adherence and reducing relapses and re-hospit
100                                              Medication adherence and relapse rates are similar acros
101            eHealth interventions may improve medication adherence and self-monitoring behavior in the
102 ined effects and impact on patient costs and medication adherence and to determine whether more inten
103                                              Medication adherence and treatment intensification have
104  normative thinking played critical roles in medication adherence and use of complementary/alternativ
105              To date, measurement of patient medication adherence and use of interventions to improve
106                                Self-reported medication adherence and visual fields were measured.
107  (ART) is generally attributed to incomplete medication adherence and/or drug resistance.
108 riant (other illicit drug use, antipsychotic medication adherence) and time-invariant (eg, genetic or
109 changes in diabetes distress, self-efficacy, medication adherence, and hemoglobin A1c values.
110 ncluding depression, provider relationships, medication adherence, and HIV-1 viral load.
111 n(a), use of intensive statin therapy, study medication adherence, and other demographic, medical his
112 survey on demographics, barriers to glaucoma medication adherence, and self-adherence (measured by th
113 bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms th
114 ivation, sex- and age-related differences in medication adherence, and sex-related differences in bod
115 ry, improving cost-effectiveness, increasing medication adherence, and supporting a comprehensive pre
116                             The odds of poor medication adherence are greater when patient-provider i
117 tcome data for patients with gout, including medication adherence, are limited.
118  Participants who reported low importance of medication adherence as a personal goal were more likely
119  monitoring (eg, environmental exposures and medication adherence) as well as electronic medical reco
120 ticipants in each study (in particular about medication adherence), as well as whether pharmacologic
121 studies (e.g. pharmacokinetic evaluations or medication adherence assessment) since it is minimally i
122 ar events (death, recurrent MI, stroke), and medication adherence at 1 year.
123 sual care resulted in significantly improved medication adherence at 15 months and statistically sign
124  Morisky instrument to assess cardiovascular medication adherence at 6 weeks post MI, we stratified p
125  than 6 weeks remained associated with lower medication adherence at 90 days (odds ratio [OR], 0.74 [
126 al attainment and lack of autonomy regarding medication adherence at transition.
127 ect Schedule; Satisfaction With Life Scale), medication adherence (Basel Assessment of Adherence to I
128                                          His medication adherence became erratic, and he missed appoi
129 t posttransplantation acute organ rejection, medication adherence becomes a key factor for successful
130 ocial variables, memory continued to predict medication adherence (beta=0.51; P=0.008), whereas execu
131  on all 3 cognitive domains predicted poorer medication adherence (beta=0.52-85; P=0.001-0.009).
132 re was no difference in tobacco cessation or medication adherence between the treatment groups (secon
133 ty presenting with MI have superior rates of medication adherence but higher rates of postdischarge r
134               Among clinical variables, poor medication adherence, but not baseline symptoms of psych
135 he causal pathway linking health literacy to medication adherence by modeling asthma illness and medi
136 ed technology-based interventions to improve medication adherence by using pharmaceutical databases,
137                Secondary outcomes were study medication adherence (by self-report and medication even
138 ibutes included age, sex, employment status, medication adherence, comorbidity status, and geographic
139 fied by text parsing also self-reported poor medication adherence compared to the 20.0% by self-repor
140                    Interventions directed at medication adherence could partly help mitigate the harm
141 t, health education, treatment readiness and medication adherence counseling, and medication coordina
142 pants were followed monthly to provide study medication, adherence counseling, and HIV testing.
143 and individually tailored risk-reduction and medication-adherence counseling.
144                                              Medication adherence data were collected continuously du
145 e claims data to obtain 1-year follow-up and medication adherence data.
146 nths after randomization, the persistence of medication adherence decreased to 69.1% (16.4%) among th
147 tered their eye drops, and had poor glaucoma medication adherence (defined as taking <=80% of prescri
148                       In Phase 1, overall CV medication adherence, defined as an MAQ score of 20, was
149 nsplantation, patients (n=44) with declining medication adherence, defined as dropping by 7% or highe
150                                              Medication adherence, defined as having medications avai
151 condary outcomes were mortality, disability, medication adherence, depression, cognition, self-rated
152 rapy; blood pressure; and patient reports of medication adherence, diabetes-related support, and emot
153                                         Poor medication adherence diminishes the health benefits of p
154 eness of methods to improve antihypertensive medication adherence, discusses the effect of drug benef
155                   The relationships of study medication adherence, dosage, and cumulative exposure (p
156 n cost-saving even if strategies to increase medication adherence doubled treatment costs.
157 ART initiation and prenatal care, along with medication adherence during pregnancy, were associated w
158 uctions in mood disorder symptoms and better medication adherence during the 2 years than patients un
159  approach compared changes in lipid-lowering medication adherence during the 24 months before and aft
160 o describe the types of objectively measured medication adherence (eg, taking, timing, dosing, drug h
161 death-censored graft loss.In addition, daily medication adherence, expressed as the percentage of dos
162 ly telephone monitoring of mood symptoms and medication adherence, feedback to treating mental health
163 ned psychosocial interventions for improving medication adherence, focusing on promising initiatives,
164   We performed a prospective cohort study of medication adherence, followed by a randomized intervent
165 months 1 and 2, later experienced lower mean medication adherence for months 6 to 12, 73% versus 92%
166 ucation with behavioral support all improved medication adherence for more than 1 condition.
167                                     Rates of medication adherence for secondary prevention therapies
168                              Patients' prior medication adherence had little impact on providers' dec
169 less of coronary revascularization strategy, medication adherence has a dramatic effect on long-term
170           A variety of strategies to improve medication adherence have been tested in clinical trials
171  to 6 weeks had no significant difference in medication adherence; however, patients with follow-up m
172  Among the 16 participants with claims data, medication adherence improved (proportion of days covere
173                                              Medication adherence improved from 59.9% at baseline to
174 t of the adapted intervention, self-reported medication adherence improved significantly in the group
175 vation and an objective surrogate measure of medication adherence in children posttransplant.
176 ospective cohort of children enrolled in the medication adherence in children who had a liver transpl
177 on focusing on lifestyle behavior change and medication adherence in cohorts with a mean age of 60 ye
178 o help to prevent HIV infection, and improve medication adherence in HIV/AIDS.
179 ion between life events and antihypertensive medication adherence in older adults and the moderating
180 ntions designed to improve asthma controller medication adherence in older adults may be enhanced by
181 Pharmacy refill records were used to compare medication adherence in outpatient veterans receiving ty
182 treatment of depressive symptoms may improve medication adherence in patients after ACS.
183  adversely affecting the quality of life and medication adherence in patients with cancer in the USA.
184 Many factors are associated with the lack of medication adherence in patients.
185  are not likely to be effective in improving medication adherence in schizophrenia.
186  Reminders from medication monitors improved medication adherence in TB patients, but text messaging
187 messaging and medication monitors to improve medication adherence in TB patients.
188 ctiveness of a medication monitor to improve medication adherence in TB patients.
189                                              Medication adherence in the 12 months after treatment in
190                                Measurements: Medication adherence in the 12 months after treatment in
191              After 6 months of intervention, medication adherence increased to 96.9% (5.2%; P<.001) a
192 ing conditions increased, and more likely as medication adherence increased.
193 haracteristics, barriers to optimal glaucoma medication adherence, interest in an eye drop aid, and s
194                                         Poor medication adherence is a pervasive problem in patients
195                                   Suboptimum medication adherence is common in the United States and
196                                     Adequate medication adherence is critical for achieving sustained
197                     Excellent posttransplant medication adherence is critical to improved outcomes.
198          These data support the concept that medication adherence is modifiable via improved care tra
199 empirical support for its ability to enhance medication adherence is scarce.
200 The effect of more generous drug coverage on medication adherence is uncertain.
201 ted through an adverse effect of cannabis on medication adherence is unclear.
202               The influence of life chaos on medication adherence is unknown.
203 udy was to determine the association between medication adherence levels and long-term MACE in these
204 talizations (moderate-strength evidence) and medication adherence (low-strength evidence) compared wi
205 atient-provider communication predicted poor medication adherence: lower patient centeredness (odds r
206                                        Lower medication adherence may be associated with a higher ris
207 transplant recipients, gender differences in medication adherence may contribute to higher graft fail
208                        Differential rates of medication adherence may partly explain links between ne
209  A pharmacy care program led to increases in medication adherence, medication persistence, and clinic
210 bed medication doses assessed via electronic medication adherence monitors) who completed the 7-month
211                     Interventions to improve medication adherence must address each patient's unique
212 ys." A patient subgroup with early declining medication adherence (n=23) experienced dramatically poo
213 predict the prognosis of patients and ensure medication adherence of patients with CSU.
214 of your medication yesterday?" The impact of medication adherence on mean deviation (MD) over time wa
215         This measure was also used to assess medication adherence on the basis of both face-to-face i
216 5.6, SD = 3.0) was inversely associated with medication adherence on univariate (P < .0001) and multi
217 s, as are lifestyle counseling, promotion of medication adherence, ongoing lipid surveillance, and me
218 nt domains can be achieved through increased medication adherence or new therapeutic strategies.
219 he non-crossover group may reflect decreased medication adherence or other related factors.
220 of the 98 patients were not classified as to medication adherence or plasma levels.
221  not differ in blood pressure, self-reported medication adherence, or diabetes-specific distress, but
222     Claims data estimating rates of glaucoma medication adherence over 4 years were used to assign pr
223 pharmacy refill data to examine patients' BP medication adherence over the prior 12 months and whethe
224 lled structural equation modelling analyses, medication adherence partly mediated the effect of conti
225 ation modelling analysis to estimate whether medication adherence partly mediated the effects of cont
226                    Prospectively, individual medication adherence patterns in 195 kidney transplant r
227 ciaries, GBTM identified 5 distinct glaucoma medication adherence patterns in both the 1-year and 4-y
228  patients who were newly prescribed glaucoma medications, adherence patterns observed in the first ye
229 depression increases mortality and decreases medication adherence, physicians need to aggressively tr
230      Depression may be an important cause of medication adherence problems, and difficulties with adh
231                      The primary outcome was medication adherence (proportion of dosages taken) asses
232            Quality-of-care measures included medication adherence, psychotherapy, and follow-up visit
233 ation of combination antiretroviral therapy, medication adherence, race, and depression status were r
234 }, 1.7-3.3]; P < .001) after controlling for medication adherence, race/ethnicity, baseline CD4 cell
235 d continued antihypertensive medication use (medication adherence rate).
236 derstood, including the possible role of low medication adherence rates that have been found in other
237 Functional Health Literacy in Adults and the Medication Adherence Rating Scale, respectively.
238 t commitment had its effect through improved medication adherence, reduced substance use or abuse, an
239 h as weight reduction, physical activity and medication adherence) remain an important and unmet chal
240 of in-person contacts with technology-driven medication adherence reminders, electronic medication re
241        Recent data suggest that the level of medication adherence required for optimal treatment effe
242 tandard care, eHealth interventions improved medication adherence (risk ratio, 1.34; CI, 1.12-2.56; I
243  as scores less than 6 on the 8-item Morisky Medication Adherence Scale (known as "MMAS-8").
244 was assessed using the 8-question (c)Morisky Medication Adherence Scale (MMAS-8).
245         Adherence was assessed using Morisky Medication Adherence Scale - 8 and adherence determinant
246 s were developed based on the 8-item Morisky Medication Adherence Scale and administered to 2 academi
247  Adherence was assessed with a self-reported medication adherence scale and IS blood trough concentra
248 instruments: the Chang scale and the Morisky medication adherence scale.
249                    At this time, 2 validated medication adherence scales were applied for assessment
250 ucoma medications and self-reported glaucoma medication adherence self-efficacy and (b) examine the r
251 ssess patient reported problems and glaucoma medication adherence self-efficacy and work with patient
252 minister glaucoma drops and patient glaucoma medication adherence self-efficacy are associated positi
253  System (MEMS) devices, and general glaucoma medication adherence self-efficacy using a previously va
254                              Higher glaucoma medication adherence self-efficacy was associated positi
255 medications had significantly lower glaucoma medication adherence self-efficacy.
256 onger reported significantly higher glaucoma medication adherence self-efficacy.
257 e reliability and concurrent validity of the Medication Adherence Self-report Inventory (MASRI) when
258 fectiveness and costs, monitoring frequency, medication adherence, side effect severity, background h
259  are needed to improve retention in care and medication adherence so that more persons in HIV care ac
260 symptoms, perceived control, social support, medication adherence, sodium intake, and self-care manag
261 teristics, illness history, clinical status, medication adherence, substance abuse, insight into illn
262 tion of patients who then self-reported poor medication adherence than an automated EHR pull alone bu
263 nt, MFG-adherence was associated with higher medication adherence than MFG-standard or treatment as u
264 n between patient-provider communication and medication adherence, there are no empirical data on how
265 oup therapy specifically tailored to improve medication adherence through a focus on the beliefs and
266  services, retain women in care, and support medication adherence throughout pregnancy and breastfeed
267                              The benefits of medication adherence to control cardiovascular disease (
268 ubjects' reported problems in using glaucoma medications, adherence to glaucoma medications utilizing
269             Secondary outcomes were rates of medication adherence, total major vascular events or rev
270 d with or without CABG, leading to increased medication adherence, trends toward improved clinical ou
271 o changes in self-reported immunosuppressive medication adherence up to 18 months after transplantati
272             For each enrollee, we quantified medication adherence using the medication possession rat
273              We measured health literacy and medication adherence using the Short Test of Functional
274                                              Medication adherence usually refers to whether patients
275                                              Medication adherence was 0.48 in the control group and 0
276                           Mean (SD) baseline medication adherence was 61.2% (13.5%).
277      During the 9-month intervention period, medication adherence was 67.9% and 78.8% in the usual ca
278                                              Medication adherence was 97% by self-report, 96% by pill
279                                         When medication adherence was added as covariate, the valproa
280                                              Medication adherence was assessed as a mediator variable
281                                              Medication adherence was assessed by telephone from resp
282                                              Medication adherence was assessed using the 8-question (
283 he relationship between baseline factors and medication adherence was assessed using univariate and m
284                                Self-reported medication adherence was assessed with 2 validated instr
285                                        Worse medication adherence was associated with loss of MD over
286                                              Medication adherence was associated with prevention of e
287                                              Medication adherence was defined as the proportion of da
288  patients' sociodemographic circumstances on medication adherence was heightened in black patients (o
289                                              Medication adherence was high and adverse event numbers
290         At 3 months, biochemically validated medication adherence was improved by 20% (95% CI 3-36%)
291                                     Baseline medication adherence was lower (318 of 482 [66.0%] vs 33
292                                              Medication adherence was measured for each patient by ob
293                                              Medication adherence was modeled as a cumulative sum of
294                                              Medication adherence was objectively measured for 21 day
295  matched control and medical home practices, medication adherence was significantly higher in medical
296                                              Medication adherence was then monitored electronically f
297 had treatment interruptions or reported poor medication adherence were more likely to have detectable
298     Limitation: Clinical outcomes related to medication adherence were not assessed.
299     To summarize recent literature regarding medication adherence with a focus on the complexities in
300              Optimizing the documentation of medication adherence would maximize the utility of this

 
Page Top